Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Works in Cardiovascular · Dermatology · Genetic & rare · Hematology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Respiratory
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is a clinical trial sponsor. It has no active clinical trials as lead sponsor; its trials since 2021 were across 9 therapeutic areas. Since 2021 it has completed 13 trials and stopped 7 early.
Trial track record · since 2021
Pipeline · 0 active trials
No active trials with this company as lead sponsor.
Questions about Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA has no active clinical trials as lead sponsor on ClinicalTrials.gov. Since 2021 it has completed 13 trials and stopped 7 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-23.
Approve Suite is not affiliated with Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.